BMJ Case Reports · 2015 · 11 citations · 17 references
MedicinePharmacologyPharmacotherapyClinical PharmacologyRenal PathologyRenal PharmacotherapyInflammatory Bowel DiseaseRenal DiseaseRenal PharmacologyRenal ToxicityTubulointerstitial DiseasesUlcerative Colitis PharmacotherapyChronic Tubulointerstitial NephritisDrug-induced Tubulointerstitial NephritisKidney Biopsy AssessmentKidney Biopsy FindingsMedication-related Tubulointerstitial NephritisNephritic FlareTubulointerstitial Nephritis SyndromeUlcerative Colitis Pathology
The 5-aminosalicylate is widely prescribed in inflammatory bowel disease patients. Its potential for renal damage has been seldom described. We report a case of a 23-year-old man who started 5-aminosalicylate after being diagnosed with ulcerative colitis. One year after, a significant decline on his creatinine clearance was noted, however, at that time, he was on an acute flare of his bowel disease and the 5-aminosalicylate dose was increased. Six months later, his renal function kept worsening and, on drug-induced toxicity suspicion, 5-aminosalicylate was halted and a kidney biopsy demonstrated a chronic tubulointerstitial nephritis. Steroids and azathioprine were started leading to partial recovery and stabilisation of his renal function. Physicians who prescribe 5-aminosalicylate to patients with inflammatory bowel disease should be aware of this adverse event.
17
Mesalazine-associated interstitial nephritis
Michael World, Paul E. Stevens, Mark A. Ashton et al. · Nephrology Dialysis Transplantation · 1996 · 113 citations
Mesalazine induced interstitial nephritis.
P.J. Thuluvath, Mary Ninkovic, J Calam et al. · Gut · 1994 · 80 citations · Full text